GlassScriptPhysician profile
Stacy K Mullet
NPI 1922071570
$10,591.40
in general payments reported to CMS, 2019-2025
36 companies · $2,140 in 2025
The $2,140 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,162 · 2022: $2,235 · 2023: $1,923 · 2024: $2,132 · 2025: $2,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,194.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,533.58 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,084.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $967.69 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $734.09 | 2022-2025 | Rexulti |
| Pfizer INC. | $729.95 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $628.73 | 2021-2025 | |
| Abbvie INC. | $604.12 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $500.54 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $453.95 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $421.86 | 2023-2025 | Auvelity, Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $361.75 | 2021-2025 | Trintellix |
| Amgen INC. | $272.19 | 2021-2025 | Repatha, Otezla, Repatha |
| Lundbeck LLC | $239.03 | 2022-2025 | Rexulti |
| Abbott Laboratories | $235.95 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $203.34 | 2021-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Mullet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.